Citations

Showing 10 of 108119 citations.

Current Use and Limitations of Cultured High-Grade Meningioma Cells in Neuro-Oncological Research – In Response to: “Caution Using Meningioma Cell Lines as Tumor Models”
Santos, Jaime L. Martínez , Suárez-Meade, Paola , Cachia, David , Lindhorst, Scott , Das, Arabinda , Martínez Santos, Jaime L

Mayo Clinic

Cancer Investigation | October 8, 2021 | Volume: 40 | Issue: 2 | Pages: 132-133

10.1080/07357907.2021.1991366 | PMID 34620006 Get It

Health Care Policy and Congenital Heart Disease: 2020 Focus on Our 2030 Future
Chowdhury, Devyani , Johnson, Jonathan N. , Baker‐Smith, Carissa M. , Jaquiss, Robert, Mahendran, Arjun , Curren, Valerie , Bhat, Aarti , Marshall, Audrey C. , Fuller, Stephanie , Marino, Bradley S. , Fink, Christina M. , Ather, Mishaal, Torentinos, Natalie, Kranz, Olivia, Thorne, Vivian, Berger, Stuart, Shaffer, Kenneth M. , Mahendran, Arjun K , Fink, Christina M , Lopez, Keila N , Baker-Smith, Carissa M , Jaquiss, Robert D.B. , Patel, Angira , Lopez, Keila N. , Frank, Lowell H. , Davies, Ryan R. , Snyder, Christopher, Saidi, Arwa S.

Mayo Clinic

Journal of the American Heart Association | October 8, 2021 | Volume: 10 | Issue: 20 | Pages: No page available

10.1161/jaha.120.020605 | PMID 34622676 Get It

Abstract The congenital heart care community faces a myriad of public health issues that act as barriers toward optimum patient outcomes. In this article, we attempt to define advocacy and policy initiatives meant to spotlight and potentially address these challenges. Issues are organized into the following 3 key facets of our community: patient population, health care delivery, and workforce. We discuss the social determinants of health and health care disparities that affect patients in the community that require the attention of policy makers. Furthermore, we highlight the many needs of the growing adults with congenital heart disease and those with comorbidities, highlighting concerns regarding the inequities in access to cardiac care and the need for multidisciplinary care. We also recognize the problems of transparency in outcomes reporting and the promising application of telehealth. Finally, we highlight the training of providers, measures of productivity, diversity in the workforce, and the importance of patient–family centered organizations in advocating for patients. Although all of these issues remain relevant to many subspecialties in medicine, this article attempts to illustrate the unique needs of this population and highlight ways in which to work together to address important opportunities for change in the cardiac care community and beyond. This article provides a framework for policy and advocacy efforts for the next decade.
Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course
Havlichek, Daniel , Choung, Rok Seon , Murray, Joseph A. , Choung, Rok Seon

Mayo Clinic

Clinical and Translational Gastroenterology | October 8, 2021 | Volume: 12 | Issue: 10 | Pages: e00394

10.14309/ctg.0000000000000394 | PMID 34620754 Get It

INTRODUCTION: Studies on eosinophilic gastroenteritis have identified broad spectrums of disease. We aimed to characterize subtypes of disease and ascertain outcomes of each group. METHODS: This is a retrospective cohort study from a large tertiary medical center including 35 patients diagnosed with eosinophilic gastroenteritis from 2007 to 2018. We defined 2 groups of patients based on clinical and laboratory findings at presentation. Severe disease was defined as having weight loss at time of presentation, hypoalbuminemia at presentation, serosal disease involvement, or anemia at diagnosis. The remaining patients were labeled as mild disease group. We collected and compared demographic data, clinical features, laboratory findings, an allergy history, and disease course of both cohorts. RESULTS: Among 35 patients with eosinophilic gastroenteritis, 18 patients met the criteria for severe disease and 17 patients for mild disease. Of the patients with severe eosinophilic gastroenteritis, 6 (38%) had remission without chronic symptoms, whereas 10 (63%) had chronic symptoms requiring chronic medical therapy. Of the mild group, 12 patients (80%) had disease remission without chronic medications. An allergy history was more common in the severe disease group (83%) compared with the mild disease group (45%). Prednisone and open capsule budesonide were the most commonly used treatment medications in both groups. DISCUSSION: Patients with eosinophilic gastroenteritis may be characterized into 2 forms. Patients with weight loss at time of presentation, hypoalbuminemia at presentation, serosal disease involvement, or anemia at diagnosis were associated with a chronic disease course requiring chronic medications.
Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study
Usón, Pedro Luiz Serrano , Samadder, N. Jewel , Riegert‐Johnson, Douglas L. , Boardman, Lisa, Ahn, Daniel H. , Faigel, Douglas O. , Pannala, Rahul , Golafshar, Michael A. , Klint, Margaret, Esplin, Edward D. , Stewart, A. Keith, Bekaii‐Saab, Tanios , Uson, Pedro L S , Riegert-Johnson, Douglas, Kunze, Katie, Golafshar, Michael , Esplin, Edward D , Bekaii-Saab, Tanios S , Boardman, Lisa, Borad, Mitesh J. , Sonbol, Mohamad Bassam , Fukami, Norio , Kunze, Katie L. , Nussbaum, Robert L.

Mayo Clinic

Clinical and Translational Gastroenterology | October 8, 2021 | Volume: 12 | Issue: 10 | Pages: e00414

10.14309/ctg.0000000000000414 | PMID 34620795 Get It

INTRODUCTION: To report the prevalence and outcomes of unselected pancreatic cancer (PC) patients with pathogenic/likely pathogenic germline variants (PGVs) detected using a universal testing approach. METHODS: We undertook a prospective, multisite study of germline sequencing using a >80 gene next-generation sequencing platform among 250 patients with PC (not selected for age or family history of cancer) between April 1, 2018, and March 31, 2020. Demographic, tumor characteristics, and clinical outcomes were compared between PGV carriers and noncarriers. RESULTS: Of 250 patients, the mean age was 65 years (SD 8.7), 56% was male, 83.6% was White, and 65.6% had advanced disease (stages III and IV). PGVs were found in 15.2% (N = 38) of patients, and 2 patients had more than 1 PGV. Variants of uncertain significance were found in 44.4% (N = 111). Family history of cancer (odds ratio: 2.36, 95% confidence interval: 1.14–5.19, P = 0.025) was associated with a higher risk of PGV. In a median follow-up of 16.5 months, the median overall survival was 16.8 months in PGV carriers compared with 16.5 months in noncarriers (hazard ratio: 0.51, 95% confidence interval: 0.25–1.01, P = 0.05). Higher levels of carbohydrate antigen 19-9 and advanced disease stages (III and IV) were associated with worse outcomes in both groups. Overall, 68% of PGV carriers had mutations in homologous recombination repair genes, including BRCA1 , BRCA2 , PALB2 , ATM , CHEK2 , NBN , and RAD51C . DISCUSSION: Universal multigene panel testing in PC reveals that 1 in 6 patients are carriers of PGV. Multigene germline testing should be used to aid in treatment selection, prognostication, and familial cancer counseling.
Response : Are Tissues a Patch Quilt of Ectopic Gene Expression?
Sommer, Steve S., Sarkar, Gobinda

Mayo Clinic

Science | October 8, 2021 | Volume: 246 | Issue: 4927 | Pages: 261-261

10.1126/science.246.4927.261-b Get It

The clinical course and role of surgery in pediatric malignant peripheral nerve sheath tumors: a database study
Lu, Victor M., Wang, Shelly, Daniels, David J., Spinner, Robert J., Levi, Allan D., Niazi, Toba N., Lu, Victor M., Wang, Shelly, Daniels, David J., Spinner, Robert J., Levi, Allan D., Niazi, Toba N.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 8, 2021 | Volume: 29 | Issue: 1 | Pages: 92-99

10.3171/2021.7.peds21263 | PMID 34624851 Get It

OBJECTIVE Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors found throughout the body, with their clinical course in children still not completely understood. Correspondingly, this study aimed to determine survival outcomes and specific clinical predictors of survival in this population from a large national database. METHODS All patients with MPNSTs aged ≤ 18 years in the US National Cancer Database (NCDB) between 2005 and 2016 were retrospectively reviewed. Data were summarized, and overall survival was modeled using Kaplan-Meier and Cox regression analyses. RESULTS A total of 251 pediatric patients with MPNSTs (132 [53%] females and 119 [47%] males) were identified; the mean age at diagnosis was 13.1 years (range 1–18 years). There were 84 (33%) MPNSTs located in the extremities, 127 (51%) were smaller than 1 cm, and 22 (9%) had metastasis at the time of diagnosis. In terms of treatment, surgery was pursued in 187 patients (74%), chemotherapy in 116 patients (46%), and radiation therapy in 129 patients (61%). The 5-year overall survival rate was estimated at 52% (95% CI 45%–59%), with a median survival of 64 months (range 36–136 months). Multivariate regression revealed that older age (HR 1.10, p < 0.01), metastases at the time of diagnosis (HR 2.14, p = 0.01), and undergoing biopsy only (HR 2.98, p < 0.01) significantly and independently predicted a shorter overall survival. Chemotherapy and radiation therapy were not statistically significant. CONCLUSIONS In this study, the authors found that older patient age, tumor metastases at the time of diagnosis, and undergoing only biopsy significantly and independently predicted poorer outcomes. Only approximately half of patients survived to 5 years. These results have shown a clear survival benefit in pursuing maximal safe resection in pediatric patients with MPNSTs. As such, judicious workup with meticulous resection by an expert team should be considered the standard of care for these tumors in children.
Factors associated with early shunt revision within 30 days: analyses from the National Surgical Quality Improvement Program
Alvi, Mohammed Ali, Bhandarkar, Archis R., Daniels, David J., Miller, Kai J., Ahn, Edward S., Alvi, Mohammed Ali , Alvi, Mohammed Ali , Alvi, Mohammed Ali, Bhandarkar, Archis R., Daniels, David J., Miller, Kai J., Ahn, Edward S.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 8, 2021 | Volume: 29 | Issue: 1 | Pages: 21-30

10.3171/2021.7.peds21222 | PMID 34624850 Get It

OBJECTIVE CSF shunt insertion is the most commonly performed neurosurgical procedure for pediatric patients with hydrocephalus, and complications including infections and catheter obstruction are common. The rate of readmission in the first 30 days after surgery has been used across surgical disciplines to determine healthcare quality. In the current study, the authors sought to assess factors associated with early shunt revision within 30 days using real-world data. METHODS Targeted shunt data set participant user files of the National Surgical Quality Improvement Program (NSQIP) from 2016 to 2019 were queried for patients undergoing a shunt procedure. A multivariable logistic regression model was performed to assess the impact of demographics, etiologies, comorbidities, congenital malformations, and shunt adjuncts on shunt revision within 30 days, as well as shunt revision due to infection within 30 days. RESULTS A total of 3919 primary pediatric shunt insertions were identified in the NSQIP database, with a mean (± SD) patient age of 26.3 ± 51.6 months. There were a total of 285 (7.3%) unplanned shunt revisions within 30 days, with a mean duration of 14.9 ± 8.5 days to first intervention. The most common reason for intervention was mechanical shunt failure (32.6% of revision, 2.4% overall, n = 93), followed by infection (31.2% of all interventions, 2.3% overall, n = 89) and wound disruption or CSF leak (22.1% of all interventions, 1.6% overall, n = 63). Patients younger than 6 months of age had the highest overall unplanned 30-day revision rate (8.5%, 203/2402) as well as the highest 30-day shunt infection rate (3%, 72/2402). Patients who required a revision were also more likely to have a cardiac risk factor (34.7%, n = 99, vs 29.2%, n = 1061; p = 0.048). Multivariable logistic regression revealed that compared to patients 9–18 years old, those aged 2–9 years had significantly lower odds of repeat shunt intervention (p = 0.047), while certain etiologies including congenital hydrocephalus (p = 0.0127), intraventricular hemorrhage (IVH) of prematurity (p = 0.0173), neoplasm (p = 0.0005), infection (p = 0.0004), and syndromic etiology (p = 0.0136), as well as presence of ostomy (p = 0.0095), were associated with higher odds of repeat intervention. For shunt infection, IVH of prematurity was found to be associated with significantly higher odds (p = 0.0427) of shunt infection within 30 days, while use of intraventricular antibiotics was associated with significantly lower odds (p = 0.0085). CONCLUSIONS In this study of outcomes after pediatric shunt placement using a nationally derived cohort, early shunt failure and infection within 30 days were found to remain as considerable risks. The analysis of this national surgical quality registry confirms that, in accordance with other multicenter studies, hydrocephalus etiology, age, and presence of ostomy are important predictors of the need for early shunt revision. IVH of prematurity is associated with early infections while intraventricular antibiotics may be protective. These findings could be used for benchmarking in hospital efforts to improve quality of care for pediatric patients with hydrocephalus.
Are Serum Ion Levels Elevated in Pediatric Patients With Metal Implants?
Mathew, Smitha , Xie, Yong, Bagheri, Leila, Claton, Liam E. , Chu, Lin, Badreldin, Amr, Wijnen, André J. van , Haft, Geoffrey F. , Milbrandt, Todd A. , van Wijnen, Andre J , Chu, Lin, Badreldin, Amr A. , Abdel, Matthew P. , Larson, A. Noelle

Mayo Clinic

Journal of Pediatric Orthopaedics | October 8, 2021 | Volume: 42 | Issue: 3 | Pages: 162-168

10.1097/bpo.0000000000001957 | PMID 34619722 Get It

Background: Previous studies report elevated serum titanium (Ti) levels in children with spinal implants. To provide additional data on this topic, we sought to assess serum ion levels at multiple timepoints in pediatric patients with growing spine devices, spinal fusion instrumentation, and extremity implants placed for fracture treatment. We hypothesized that serum Ti, cobalt (Co), and chromium (Cr) levels would be elevated in pediatric patients with growing spine devices compared with patients with extremity implants. Methods: Pediatric patients undergoing any primary spine implant placement, those with spine implant revision or removal surgery and patients with other appendicular implant removal had serum Ti, Co, and Cr ion levels drawn at the time of surgery. Fifty-one patients (12 growing spine devices, 13 fusions, and 26 extremity implants) had one set of labs, 31 of whom had labs drawn both preoperatively and postoperatively. Biopsies obtained from tissue specimens at the time of implant revision were analyzed histologically for the presence of metal debris and macrophage activity. Results: Patients with growing spine implants had elevated serum Ti (3.3 vs. 1.9 ng/mL, P=0.01) and Cr levels (1.2 vs. 0.27 ng/mL, P=0.01) in comparison to patients with fusion rods or extremity implants. With respect to patients with extremity implants, patients with growing spine devices had elevated serum Ti (3.3 vs. 0.98 ng/mL, P=0.013), Co (0.63 vs. 0.26 ng/mL, P=0.017), and Cr levels (1.18 vs. 0.26 ng/mL, P=0.005). On matched pairs analysis, patients who had labs drawn before and after spine implantation had significant increase in serum Ti levels (0.57 vs. 3.3 ng/mL, P=0.02). Histology of tissue biopsies adjacent to growing spine implants showed presence of metal debris and increased macrophage activity compared with patients with extremity implants. Conclusion: Serum Ti, Co, and Cr levels are elevated in children with spinal implants compared with those with extremity implants, particularly in those with growing spine devices. However, the clinical significance of these findings remains to be determined. Level of Evidence: Level II—prospective comparative study.
Pediatric Extramedullary Epidural Spinal Teratomas: A Case Report and Review of the Literature
Deckey, David G. , Fernandez, Andrea, Lara, Nina , McClendon, Jamal, Bennett, David M. , Lara, Nina J , Bennett, David M , Taylor, Steve

Mayo Clinic

Case Reports in Orthopedics | October 8, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-8

10.1155/2021/6702972 | PMID 34659854 Get It

Background. Teratomas in the pediatric population are most commonly found in the sacrococcygeal region. Pediatric intraspinal teratomas, however, are an exceedingly rare central nervous system (CNS) neoplasm. The clinical presentation of these intraspinal neoplasms can vary significantly and thus can be difficult to identify in infants less than one year of age where verbal expression and motor development are still lacking. Case Description. A 7-month-old, previously healthy male presented with a thoracic scoliosis and an asymptomatic right midupper thoracic spinal prominence present since birth. MRI revealed an extensive heterogenous mass in the right epidural space from T5-T6 and the right paravertebral space, resulting in severe spinal stenosis. Outcome. Complete resection of the tumor, including a three-level neurotomy, was achieved by posterior decompression/laminectomy. The final tumor was consistent with a mature teratoma. The surgical resection was performed without any immediate complications. Conclusions. Extramedullary epidural teratomas are exceptionally rare tumors in the pediatric population. Clinical presentation can be ambiguous, particularly in an infant. MRI was useful in suggesting a teratoma as a potential diagnosis and for postoperative surveillance for recurrence. However, histopathological analysis remains the gold standard for definitive diagnosis. Surgical resection is the mainstay of treatment, especially in the setting of cord compression and progressive loss of motor function. Close follow-up is crucial to monitor for progressive spinal deformity or recurrence.
A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD
Falcinelli, Emanuela , Bhotla, Haripriya Kuchi , Mezzasoma, Anna Maria, Guglielmini, Giuseppe , Tischer, Alexander , Moon‐Tasson, Laurie, Auton, Matthew , Falcinelli, Emanuela , Guglielmini, Giuseppe , Moon-Tasson, Laurie, Auton, Matthew , Tischer, Alexander , Bury, Loredana , Gresele, Paolo

Mayo Clinic

Blood Advances | October 8, 2021 | Volume: 6 | Issue: 7 | Pages: 2236-2246

10.1182/bloodadvances.2021005463 | PMID 34619770 Get It

Abstract Gain-of-function (GOF) variants in GP1BA cause platelet-type von Willebrand disease (PT-VWD), a rare inherited autosomal dominant bleeding disorder characterized by enhanced platelet GPIbα to von Willebrand factor (VWF) interaction, and thrombocytopenia. To date, only 6 variants causing PT-VWD have been described, 5 in the C-terminal disulfide loop of the VWF-binding domain of GPIbα and 1 in the macroglycopeptide. GOF GP1BA variants generate a high-affinity conformation of the C-terminal disulfide loop with a consequent allosteric conformational change on another region of GPIbα, the leucine-rich-repeat (LRR) domain. We identified a novel GP1BA variant (p.Arg127Gln) affecting the LRR5 domain of GPIbα in a boy with easy bruising and laboratory test results suggestive of PT-VWD. We thus aimed to investigate the impact of the p.Arg127Gln variant on GPIbα affinity for VWF and GPIbα structure. Chinese hamster ovary cells expressing p.Arg127Gln GPIbα showed increased binding of VWF induced by ristocetin and enhanced tethering on immobilized VWF as compared with cells expressing wild-type GPIbα. Surface plasmon resonance confirmed that p.Arg127Gln enhances the binding affinity of GPIbα for VWF. Hydrogen-deuterium exchange mass spectrometry showed that p.Arg127Gln of LRR, while having little effect on the dynamics of the LRR locally, enhances the conformational dynamics of the GPIbα C-terminal disulfide loop structure. Our data demonstrate for the first time that GOF variants outside the GPIbα C-terminal disulfide loop may be pathogenic and that aminoacidic changes in the LRR may cause allosterically conformational changes in the C-terminal disulfide loop of GPIbα, inducing a conformation with high affinity for VWF.